Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
466.620USD
-0.170-0.04%
Market hours （ET）Quotes delayed by 15 min
118.60BMarket Cap
27.44P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Vertex Pharmaceuticals Inc is 8.18, ranking 50 out of 157 in the Pharmaceuticals industry. The average price target is 492.50, with a high of 604.00 and a low of 330.00.
Analyst Rating
Based on
34
analysts
Buy
Current Rating
549.861
Target Price
+21.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Vertex Pharmaceuticals Inc
VRTX
34
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Bristol-Myers Squibb Co
BMY
32
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Vertex Pharmaceuticals Inc's expected revenue for the next quarter?
Vertex Pharmaceuticals Inc's expected revenue is 3.22B.
What is Vertex Pharmaceuticals Inc's price target?
Analysts forecast that Vertex Pharmaceuticals Inc's price target is USD 492.50, with the highest forecast at USD 604.00 and the lowest forecast at USD 330.00.
How have Vertex Pharmaceuticals IncVRTX's recent earnings per share performed?
The market expectation was USD 4.06, while Vertex Pharmaceuticals IncVRTX's earnings per share (EPS) for the previous quarter was USD 4.70. EPS for the next quarter is expected at USD 4.74.
What is the analyst rating for Vertex Pharmaceuticals Inc?
Based on the ratings of Vertex Pharmaceuticals Inc's stock from 34 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
